Duality Biotherapeutics, Inc.

映恩生物

09606.HK

Develops antibody-drug conjugate (ADC) therapeutics for cancers and autoimmune diseases. Lead candidates include a HER2 ADC and a B7-H3 ADC, plus additional clinical-stage and preclinical ADCs. Incorporated in 2019, with candidates among the most clinically advanced globally per Frost & Sullivan.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Overseas markets and operations
• Key long-term agreements
• Losses and path to profitability
• Net current liabilities or net liabilities
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Goodwill, intangibles and asset impairment
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Non-recurring gains and losses
• Material share-based payments
• Chapter 18A biotech